503 results about "Vascular Disorder" patented technology

The invention provides an echocardiogram video abstraction method based on a hierarchical space-time attention mechanism, and the method comprises the steps: obtaining an echocardiogram, inputting the echocardiogram into an anatomy and physiological basic model of a key frame recognition task, and obtaining key frame information; inputting the key frame information into a multi-dimensional spatial-temporal feature extraction model to obtain feature information and frequency domain information; fusing the feature information and the frequency domain information; performing key frame enhancement processing on the fusion information by adopting an SE channel attention mechanism to obtain key frame anatomical feature expression; processing the key frame anatomical feature expression by adopting a key frame backtracking strategy and a classification network to obtain a key frame identification classification result; performing left ventricle segmentation on the classified image by adopting an improved U-Net left ventricle region segmentation network; estimating the area and volume of the left ventricle based on a segmentation result; fusing the estimated left ventricular area and volume by adopting a hierarchical attention mechanism and a cross-layer information fusion strategy to obtain a ventricular volume result; according to the method, through abstract extraction of the key information of the ultrasonic cardiac video, the clinical practicability of intelligent screening and auxiliary diagnosis of cardiovascular diseases based on ultrasonic is improved.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention discloses a quinazolinone compound as well as a preparation method, a pharmaceutical composition and application thereof, and relates to the technical field of pharmaceutical chemistry. In particular to a quinazolinone compound as shown in a formula I or pharmaceutically acceptable salt, prodrug, stereoisomer, diastereoisomer, enantiomer, tautomer, solvate, salt of solvate, polymorphic substance and isotope labeled compound of the quinazolinone compound. The quinazolinone compound designed and synthesized by the invention can effectively inhibit TAK1 protein activity, achieves an excellent curative effect at a molecular level, and can be applied to preparation of medicines for treating and / or preventing inflammation, chronic fibrosis diseases, hyperproliferative diseases and cardiovascular diseases.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

The invention relates to the field of small cerebral vessels, in particular to a medical image-based early feature analysis method and system for small cerebral vessels. The method comprises the following steps: acquiring a brain magnetic resonance image data set, preliminarily analyzing brain small vessel local features based on the brain magnetic resonance image data set, and generating a basic brain small vessel feature set; obtaining a clinical parameter set of the patient, analyzing the recessive influence factors according to the clinical parameter set of the patient, and generating a brain small vessel optimized feature set based on the basic brain small vessel feature set and in combination with the recessive influence factors; and performing visual fusion rendering according to the brain small vessel optimized feature set, and generating and outputting a record analysis log. In the process of early feature analysis of small cerebral vessels, doctors are assisted in accurately identifying the enlargement of the gaps around the vessels and simulators thereof, the misjudgment risk is effectively reduced, and the accuracy and reliability of early diagnosis of small cerebral vessel diseases are improved.

The invention is applied to the technical field of health-care products, and discloses a sea-buckthorn soft capsule, which comprises a capsule shell and a content, the capsule shell is composed of gelatin, water, glycerin and an auxiliary material, the auxiliary material is a preservative or a plasticizer, the content is composed of one of seabuckthorn seed oil or fruit oil, seabuckthorn powder and an auxiliary material, the auxiliary material is one of a suspending aid and an antioxidant or a mixture of the suspending aid and the antioxidant, the seabuckthorn powder is rich in flavone, and the auxiliary material is a mixture of the suspending aid and the antioxidant. The soft capsule has the effects of lowering lipid, softening blood vessels and preventing vascular diseases. According to the hippophae rhamnoides soft capsule, a product capsule shell is prepared from gelatin, water and glycerin according to a specific proportion, it can be guaranteed that the capsule shell has proper hardness and elasticity and is convenient to process and store, hippophae rhamnoides seed (fruit) oil and hippophae rhamnoides powder in the content are matched according to a reasonable proportion, the hippophae rhamnoides powder is rich in flavone, and the hippophae rhamnoides powder and the hippophae rhamnoides seed (fruit) oil act the effects of lowering lipid, softening blood vessels and preventing vascular diseases can be better exerted.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

A computer-implemented method for predicting cardiovascular disease risk, the method including: receiving a first patient history data comprising imaging data and / or non-imaging data for a patient at a first time point; selecting prediction report parameters defining a type of cardiovascular event and a risk prediction time scale; processing the first patient history data using a trained machine learning model configured to predict disease onset, progression, and / or regression over time, wherein the trained machine learning model is trained using patient subsets created based on patient history characteristics and outcomes; generating a risk prediction for the selected type of cardiovascular event over the selected risk prediction time scale based on the processed first patient history data; generating a risk prediction report based on the risk prediction; and outputting the risk prediction report.

A prediction system includes: a terminal; and a processor, communicatively coupled to the processor. The processor is configured to: acquire medical treatment information including images captured at at least one of before, during, immediately after, and after a predetermined period from treatment of a patient with a symptom of a vascular disease; classify a condition of the patient based on a classification image; learn the medical treatment information in association with the condition of the patient; and predict at least one of a treatment effect and a prognosis when treatment intervention is performed for the patient based on a learning result.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

The invention belongs to the technical field of life science, and particularly relates to a biological age construction method and system based on clinical physiological and biochemical indexes and an accelerated aging condition evaluation method. Initial clinical indexes and actual ages of the participants are collected, and outcome variables of the participants are recorded in a follow-up visit mode and comprise death or survival conditions, cardiovascular disease morbidity conditions and corresponding event occurrence time; screening key clinical indexes according to absolute Spearman correlation coefficients of the initial clinical indexes and actual ages; the key clinical indexes and the actual age are used as independent variables, death is used as a dependent variable, and a relational expression between the biological age and the key clinical indexes and the actual age is obtained through a Gompertz proportional risk model. According to the method, the biological age is calculated based on conventional clinical physiological and biochemical indexes, and compared with the biological age calculated based on omics and image data, the method can be more conveniently and efficiently applied to the majority of people, and aging evaluation is incorporated into conventional medical care items.

The present disclosure relates to small molecule modulators of CX3CR1, pharmaceutical compositions thereof and uses thereof for the treatment of cardiovascular disease.

Use of an NLRP3 inhibitor for treating cerebrovascular diseases. Specifically, the present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating cerebrovascular diseases, wherein each substituent is as defined in the description.

The present invention provides: a novel azabicyclo derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating autotaxin-related diseases, comprising the same as an active ingredient. The azabicyclo derivative compound according to the present invention exhibits excellent inhibitory activity against autotaxin, and thus can be used for treating and preventing diseases associated with autotaxin inhibition. The compounds can be used for treating diseases such as fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancers and cancer metastases, ocular diseases, cholestatic and other forms of chronic pruritus, and acute or chronic organ transplant rejection.

Disclosed is a quinoline compound and a use thereof. A quinoline derivative of the present invention is a compound having phosphodiesterase 3A (PDE3A) inhibitory activity, has important potential therapeutic value, and is used in the treatment of cerebrovascular diseases or in dementia drugs.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The invention belongs to the field of pathologies affecting the central nervous system: in particular, severe cerebral pathologies, more particularly those restricted by the presence of the blood-brain barrier (BBB): gliomas, cerebral metastases, neurodegenerative diseases (e.g. Alzheimer's, Parkinson's or ALS), genetic diseases (Huntington's, myopathies, Leigh syndrome, Rett syndrome), but also to the field of cancers, musculoskeletal and immunological disorders, vascular diseases (thrombus) in numerous organs (e.g. liver, kidney or muscle) and in combination with numerous therapeutic approaches (e.g. chemotherapy, immunotherapy, targeted therapy or gene therapy). The invention relates to a microbubble comprising a fluorinated polymer or copolymer and a fluorinated gas, to the use thereof and also to the polymer or copolymer intermediate compounds.

This disclosure relates to an oral pharmaceutical formulation comprising a compound of formula I or a pharmaceutically acceptable salt thereof. In formula JPEG2026528933000058.jpg30170, R, A, and n are as described herein. This disclosure also relates to the preparation processes thereof, as well as their use in the treatment of disorders such as cardiovascular and metabolic disorders, including diabetes.

The present invention are co-crystals of Uric Acid with increased solubility with respect to crystals of Uric Acid, suitable for the pharmaceutical use. The invention comprises co-crystals with L-lysine, L-arginine, ethylene diamine, and tromethamine as co-formers, pharmaceutical compositions thereof and their therapeutical use in the prevention or treatment of cerebrovascular diseases.

The invention discloses a nattokinase product for preventing and / or treating atherosclerosis and application of the nattokinase product. Cardiovascular diseases become the primary reason of human death, and the vascular plaque problem caused by atherosclerosis is always a difficult problem to be solved urgently. Blood vessel stenosis caused by plaques is a main cause of cerebral arterial thrombosis, and traditional medicines and operations face the problems of low compliance, side effect risk, indication limitation and the like. The invention provides nattokinase or a product thereof for high-risk groups with cardiovascular diseases, and the nattokinase or the product thereof is preferably in a non-drug form. As a precise nutrition intervention means, nattokinase is effective in plaque progress inhibition, unique in effect, safe to eat, convenient, easy to implement and wide in applicable crowd. The invention provides a new thought and method for management of vascular plaques and prevention and treatment of cardiovascular diseases.

In one aspect, the disclosure relates to a method for treating clonal hematopoiesis of indeterminate potential (CHIP) in a subject, the method including at least the step of administering to the subject a therapeutically effective amount of an inhibitor of receptor activator of nuclear factor κB ligand (RANKL), such as denosumab, a therapeutically effective amount of an anti-inflammatory agent, such as colchicine, or both. In a further aspect, performing the method reduces growth of one or more clones or causes the size of one or more clones to remain constant. In another aspect, each month of performing the method can result in a further reduction of annual clonal growth rate. In a still further aspect, performing the method further treats or prevents a cardiometabolic disease, a cardiovascular disease, or a myeloproliferative disease or disorder. Also disclosed are methods for reducing or maintaining clonal hematopoiesis risk score (CHRS) in a subject.

The invention relates to an intelligent monitoring and risk early warning system for cardiovascular acute and critical diseases, which is characterized in that electrocardiosignals are acquired in real time through a wearable twelve-lead ECG monitor (ADS1298 chip, 512Hz sampling), and the electrocardiosignals are encrypted and transmitted to a cloud end through an MQTT protocol in combination with edge end wavelet denoising and QRS wave detection. And the cloud end adopts a multi-modal fusion engine, integrates a random forest-XGBoost hybrid model, performs modeling based on a postoperative patient physiological index time sequence, predicts the risk through Kalman filtering and triggers secondary early warning. Clinical tests in a third-A hospital prove that the end-to-end response time is 2.8 seconds, the D2B time is shortened to 70 minutes, and the occurrence rate of main adverse cardiovascular events in 30 days after operation is reduced by 47%. According to the invention, the limitation of traditional single-mode monitoring is broken through, a whole-process closed loop of collection-analysis-intervention is constructed, and an intelligent solution is provided for prevention and control of cardiovascular acute and critical diseases.

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

A pro-inflammatory and vasoconstrictor and endothelin-1 (ET-1) are pathogenic molecules related to a series of cardiovascular diseases. Unlike ET-1 signaling for vasoconstriction of the main artery, we have proven herein that coronary microvessels exhibit a unique signaling mechanism for constriction (independent of PKC, CPI-17, and intracellular calcium storage). The pathophysiological level of ET-1 acts preferentially on the microvessels to exert persistent vasoconstriction by activating Rho kinase upon binding to ETAR of the ET-1 receptor. The ETAR antagonist BQ123 only blocks but cannot reverse vasoconstriction against ET-1. In contrast, ROCK inhibitors (e.g., H-1152) are effective to reverse arteriolar systole against ET-1. Thus, ROCK inhibition is a potent and specific choice for the treatment of coronary ischemic disease (abnormal vasoconstriction) associated with microvascular dysfunction due to excessive production of ET-1. The ROCK inhibitors may also be used to treat microvascular diseases associated with diabetic retinopathy as well as microvascular dysfunction caused by cancer therapy or immunosuppressive drugs. Since H-1152 can also reduce the basal tension of microvessels, a ROCK inhibitor is also a good diagnostic agent when used during angiography or by a non-invasive method.